NTRA

NASDAQ · Biotechnology

Natera Inc

Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$259.97

+25.21 (+10.74%)

NTRA News1 articles

Natera Shares Slide Despite FDA Approval for Bladder Cancer Test

Natera shares dropped 5.36% Friday, even after the FDA approved its Signatera CDx test for use with Genentech's Tecentriq in muscle-invasive bladder cancer. The stock closed at $186.36.